Literature DB >> 23997943

A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers.

Christopher Urban1, Milan J Anadkat.   

Abstract

Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.

Entities:  

Keywords:  Cetuximab; panitumumab; regorafenib

Year:  2013        PMID： 23997943      PMCID： PMC3712297          DOI： 10.3978/j.issn.2078-6891.2013.033

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  28 in total

Review 1.  Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.

Authors:  Aminah Jatoi; Phuong L Nguyen
Journal:  Oncologist       Date:  2008-11-06

2.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

3.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Authors:  Aminah Jatoi; Shaker R Dakhil; Jeff A Sloan; John W Kugler; Kendrith M Rowland; Paul L Schaefer; Paul J Novotny; Donald B Wender; Howard M Gross; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-09-06       Impact factor: 3.603

4.  A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

Authors:  J Tol; M Koopman; C J Rodenburg; A Cats; G J Creemers; J G Schrama; F L G Erdkamp; A H Vos; L Mol; N F Antonini; C J A Punt
Journal:  Ann Oncol       Date:  2008-02-13       Impact factor: 32.976

5.  Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.

Authors:  Celia Requena; Beatriz Llombart; Onofre Sanmartín
Journal:  Cutis       Date:  2012-08

6.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

Authors:  A Osio; C Mateus; J-C Soria; C Massard; D Malka; V Boige; B Besse; C Robert
Journal:  Br J Dermatol       Date:  2009-04-10       Impact factor: 9.302

9.  Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.

Authors:  Nuno Miguel Bouças Vasconcelos de Noronha e Menezes; Ricardo Lima; Ana Moreira; Paulo Varela; Ana Barroso; Armando Baptista; Bárbara Parente
Journal:  Eur J Dermatol       Date:  2009-03-03       Impact factor: 3.328

Review 10.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603
View more
  6 in total

1.  Targeted therapies in colorectal cancer: the dos, don'ts, and future directions.

Authors:  Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2013-09

Review 2.  A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies.

Authors:  Ilufredo Y Tantoy; Janine K Cataldo; Bradley E Aouizerat; Anand Dhruva; Christine Miaskowski
Journal:  Cancer Nurs       Date:  2016 Nov-Dec       Impact factor: 2.760

Review 3.  Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

Authors:  B McLellan; F Ciardiello; M E Lacouture; S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2015-06-01       Impact factor: 32.976

4.  Panitumumab-Induced Paronychia: A Case Report and a Brief Review of the Literature.

Authors:  Ahu Yorulmaz; Basak Yalcin
Journal:  Skin Appendage Disord       Date:  2020-12-03

5.  Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts.

Authors:  Michele De Tursi; Marinella Zilli; Consiglia Carella; Matteo Auriemma; Maria Nadia Lisco; Marta Di Nicola; Giuseppe Di Martino; Clara Natoli; Paolo Amerio
Journal:  Onco Targets Ther       Date:  2017-06-16       Impact factor: 4.147

6.  Molecular Profiling of EGFR Status to Identify Skin Toxicity in Colorectal Cancer: A Clinicopathological Review.

Authors:  C M Popa; C Lungulescu; S L Ianoși; I Cherciu; M Schenker; A Săftoiu
Journal:  Curr Health Sci J       Date:  2019-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.